The COVID-19 pushes up demand, and API manufacturers expand 4 times

Recently, the Israeli raw material supplier Wavelength Pharmaceuticals has substantially increased the production of APIs for the treatment of patients with severe respiratory diseases. Due to the new global epidemic situation, the demand for Midazolam, Cisatracurium and Rocuronium has rapidly increased.



Ifftach Seri, CEO of Wavelength, said: "Over the past 30 years, we have invested in the establishment of a world-class company dedicated to providing high-quality APIs for a range of products. The regulatory record allows us to quickly supply life-saving medicines that are urgently needed by new patients with critical illness. We are proud of our experienced company team, who are constantly producing and supplying essential APIs for European and American patients. With their efforts, I The company's current output has tripled 3-4 times. "



The company also announced the launch of a new API R & D and Manufacturing Contract Service (CDMO), which will use its core strengths in complex chemistry, crystal shape and particle design to provide customized solutions for the development and production of new APIs. Supported by comprehensive regulations, Wavelength can meet a wide range of production needs from preclinical experimental requirements in grams to commercial production in tons.